Clinical Study
Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
Table 3
The incidence of hepatotoxicity caused by EGFR-TKIs.
| Study name | Incidence of hepatotoxicity Any grade | Grade 3, 4 | Ratio of patients with EGFR gene mutation | Ethnicity/race | Number of patients who administrate EGFR-TKIs | References |
| Gefitinib | | | | | | |
| V15-32 | 24.2% | 11.1% | 54.% | Japanese | 244 | Maruyama et al. [13] | IPASS | | 9.4% | 21.7% | Asian | 607 | Mok et al. [14] | NEJ002 | 55.3% | 26.3% | 100% | Japanese | 114 | Maemondo et al. [5] | WJTOG3405 | 70.1% | 24% | | Japanese | 177 | Mitsudomi et al. [6] |
| Erlotinib | | | | | | |
| Phase II study in Japan | 24.2% | 3.2% | Not described | Japanese | 62 | Kubota et al. [20] | OLCSG trial 0705 | 30% | 0% | 0% | Japanese | 30 | Yoshioka et al. [21] | Trust | <1% | <1% | Not described | White, Asian, Black | 6580 | Reck et al. [22] |
|
|
Abbreviations: EGFR: epidermal growth factor receptor; TKIs: tyrosine kinase inhibitors.
|